4.7 Article

Epigenetic control of MAGE gene expression by the KIT tyrosine kinase

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 127, Issue 9, Pages 2123-2128

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1038/sj.jid.5700836

Keywords

-

Categories

Funding

  1. NIAMS NIH HHS [KO1 AR048587, R01AR043356] Funding Source: Medline

Ask authors/readers for more resources

The Class I MAGE proteins include the MAGE-A, MAGE-B, and MAGE-C antigens, which are normally expressed only in male germ cells but may be aberrantly expressed in melanomas and other tumors. It is known that MACE gene expression is epigenetically repressed by promoter region methylation in most cells but factors controlling MAGE gene promoter methylation have not been identified. Using transcript microarray analysis and immunoblotting we found that MAGE-A and MAGE-C mRNA and protein are selectively clownregulated by pharmacologic inhibition of KIT in KIT-dependent mast cell lines. Methylation-specific polymerase chain reaction studies showed that the MAGE-A3 and MAGE-C2 gene promoter regions were de-methylated in the presence of activated KIT but became methylated on inhibition of KIT, consistent with the downregulation of mRNA and protein. This is early evidence of a tyrosine kinase affecting MACE gene promoter region methylation and expression, and represents early evidence of a tyrosine kinase in the epigenetic control of gene expression. MAGE proteins suppress apoptosis and promote tumor survival, and are novel targets for functional manipulation and immunotherapy. Understanding the factors controlling MACE gene expression may allow more effective therapeutic strategies targeting MAGE antigens.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available